Cited by 12Bacterial Infections and VaccinesPneumonia and Respiratory InfectionsStreptococcal Infections and Treatments

Magnesium therapy improves outcome in Streptococcus pneumoniae meningitis by altering pneumolysin pore formation

Open access
Hupp, Sabrina, Ribes, Sandra, Seele, Jana, Bischoff, Carolin, Förtsch, Christina, Maier, Elke, Benz, Roland, Mitchell, Timothy J +2 more·2017·British Journal of Pharmacology

Abstract

BACKGROUND AND PURPOSE: Streptococcus pneumoniae is the most common cause of bacterial meningitis in adults and is characterized by high lethality and substantial cognitive disabilities in survivors. Here, we have studied the capacity of an established therapeutic agent, magnesium, to improve survival in pneumococcal meningitis by modulating the neurological effects of the major pneumococcal pathogenic factor, pneumolysin. EXPERIMENTAL APPROACH: We used mixed primary glial and acute brain slice cultures, pneumolysin injection in infant rats, a mouse meningitis model and complementary approaches such as Western blot, a black lipid bilayer conductance assay and live imaging of primary glial cells. KEY RESULTS: in animals and 2 mM in cultures) prevented pneumolysin-induced brain swelling and tissue remodelling both in brain slices and in animal models. In contrast to other divalent ions, which diminish the membrane binding of pneumolysin in non-therapeutic concentrations, magnesium delayed toxin-driven pore formation without affecting its membrane binding or the conductance profile of its pores. Finally, magnesium prolonged the survival and improved clinical condition of mice with pneumococcal meningitis, in the absence of antibiotic treatment. CONCLUSIONS AND IMPLICATIONS: Magnesium is a well-established and safe therapeutic agent that has demonstrated capacity for attenuating pneumolysin-triggered pathogenic effects on the brain. The improved animal survival and clinical condition in the meningitis model identifies magnesium as a promising candidate for adjunctive treatment of pneumococcal meningitis, together with antibiotic therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.14027

Cites

71 of 71 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several potential targets and interventions have been tested in animal models and small retrospective human studies.

    “Although several potential targets and interventions have been tested in animal models 57 and small retrospective human studies 55”
  • Rifampicin has shown promise as a potential adjunct in human studies.

    “has also shown promise as a potential adjunct in human studies.55,56”

    From Community-acquired acute bacterial meningitis in adults: a clinical update (2019) · cites this paper as [55]

    The Discussion proposes magnesium as an adjunct and recommends a future clinical study; it does not report human studies of rifampicin. Searches for “rifampicin” and “rifampin” found rifampin only in reference titles concerning experimental or infant-rat meningitis, not evidence for the attributed human-study claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured
  • Rifampicin has significant anti-inflammatory properties.

    “Rifampicin although bacteriostatic has significant anti-inflammatory properties”

    From Community-acquired acute bacterial meningitis in adults: a clinical update (2019) · cites this paper as [55]

    The Introduction (page unavailable) discusses reduced release of neurotoxic factors with non-bacteriolytic antibiotics, but does not identify rifampicin as having anti-inflammatory properties. Searches for “rifampicin anti-inflammatory,” “rifampin,” and “anti-inflammatory” found rifampin only in reference titles, not a statement supporting the claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hupp, S., Ribes, S., Seele, J., Bischoff, C., Förtsch, C., Maier, E., Benz, R., Mitchell, T. J., Nau, R., & Iliev, A. I.
Affiliations
  • University of Bern (CH)
  • Universitätsmedizin Göttingen (DE)
  • University of Würzburg (DE)
  • University of Birmingham (GB)
Corresponding author
Iliev, Asparouh I
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2017-10-19
Volume
174
Issue
23
Pages
4295-4307
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2750741543
Cited by
12
References
71
Citations by year
2023: 4 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 1
FWCI
1.33
Type
journal article
Language
en
Open access
Locations
  • British Journal of Pharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
Funders
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A_160136/1)
  • Universität Bern
  • Deutsche Forschungsgemeinschaft
  • Julius-Maximilians-Universität Würzburg
  • Wellcome Trust (WT094762MA)
  • European Science Foundation
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
  • Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Streptococcal Infections and Treatments
Keywords
magnesium supplementation, Streptococcus pneumoniae, pneumococcal meningitis, pneumolysin, pore formation, divalent ions, cerebral edema, glial cells, neuroprotection, adjunctive therapy
MeSH terms
Animals, Bacterial Proteins, Brain, Disease Models, Animal, Female, Meningitis, Pneumococcal, Mice, Inbred C57BL, Neuroglia, Streptococcus pneumoniae, Streptolysins, Magnesium Chloride, Survival Rate, Rats, Sprague-Dawley, Mice, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review